<DOC>
	<DOCNO>NCT01582490</DOCNO>
	<brief_summary>This Phase 4 , prospective , open-label , non-randomized , sequential study two treatment group differ technique use EXPAREL administration ( instillation infiltration ) .</brief_summary>
	<brief_title>Study EXPAREL Patients Undergoing Breast Augmentation</brief_title>
	<detailed_description>Each subject underwent bilateral augmentation mammoplasty receive dose EXPAREL . This primary objective study assess efficacy EXPAREL administer via infiltration versus instillation part bilateral augmentation mammoplasty . The secondary objective assess efficacy measure safety profile EXPAREL .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Female , 1875 year age inclusive . American Society Anesthesiologists ( ASA ) physical status 13 . Undergoing bilateral augmentation mammoplasty without concurrent surgical procedure ( ) . Physically mentally able participate study complete study assessment . Able give fully inform consent participate study demonstrate good understanding risk benefit study component . History hypersensitivity idiosyncratic reaction amidetype local anesthetic . Any subject whose anatomy surgical procedure might , opinion Investigator , preclude potential successful local administration EXPAREL . Subjects currently pregnant may become pregnant course study . Any subject opinion Investigator might harm poor candidate participation study . Subjects receive investigational drug within 30 day prior study drug administration , plan administration another investigational product procedure participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Mammoplasty</keyword>
	<keyword>Postoperative pain</keyword>
	<keyword>Analgesia</keyword>
</DOC>